Liquid fibrin sealant - OMRIX Biopharmaceuticals

Drug Profile

Liquid fibrin sealant - OMRIX Biopharmaceuticals

Alternative Names: Evicel; Quixil

Latest Information Update: 04 Jun 2015

Price : $50

At a glance

  • Originator OMRIX Biopharmaceuticals
  • Developer Ethicon; OMRIX Biopharmaceuticals
  • Class Acute-phase proteins; Adhesives; Antifibrinolytics; Antihaemorrhagics; Blood coagulation factors; Coagulants; Serine endopeptidases
  • Mechanism of Action Fibrinogen replacements; Thrombin replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Surgical blood loss

Most Recent Events

  • 27 May 2015 Ethicon plans a phase III trial for Surgical blood loss in USA, Australia, Belgium, Germany and United Kingdom (NCT02457546)
  • 17 Apr 2014 Registered for Surgical blood loss in New Zealand (Topical)
  • 22 Oct 2012 Registered for Surgical blood loss in Australia (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top